•
Dec 31, 2021
Disc Medicine Q4 2021 Earnings Report
Reported financial results for the year ended December 31, 2021.
Key Takeaways
Gemini Therapeutics reported its full year 2021 financial results, revealing a net loss of $71.9 million. The company is currently evaluating strategic options to maximize shareholder value.
Gemini Therapeutics is evaluating strategic options.
Net loss for the full year 2021 was $71.9 million.
Research and development expenses were $48.7 million for the full year 2021.
Cash and cash equivalents totaled $136.6 million as of December 31, 2021.